Precision Lung Cancer Survivorship Care Intervention
The overarching goal of the Kentucky LEADS Collaborative Lung Cancer Survivorship Care program is to reduce the burden of lung cancer by offering an innovative survivorship care approach that improves lung cancer quality of life, overcomes lung cancer stigma, and helps survivors engage with care. The project involves a two-group parallel randomized clinical trial comparing the impact of the Kentucky LEADS Collaborative Lung Cancer Survivorship Care program (KLCLCSC) among lung cancer survivors (N=300) against an enhanced usual care condition (bibliotherapy+assessment) on quality of life outcomes.
Checked against the public recordLast updated Feb 23, 2026 · Source: ClinicalTrials.gov
What this study is about
- Purpose
- Supportive Care
- Study type
- Interventional
- Phase
- Not applicable
- Sponsor
- Jerod L Stapleton, PhD
- Interventions being studied
- Behavioral: Kentucky LEADS Collaborative Lung Cancer Survivorship Care Program; Behavioral: Enhanced Usual Care
How this study is categorized
These labels come from structured fields and exact terms in the public record.
Who may be able to participate
Inclusion Criteria: * Have been diagnosed with lung cancer * Reside in a rural county as determined by a Rural Urban Continuum Code (RUC) of 4 or higher * Be at least 18 years of age or older * Be able to communicate effectively in English Exclusion Criteria: * Have significant psychiatric disturbance that requires a higher level of care * Have substance abuse/dependence that requires a higher level of care * Are participating in another lung cancer survivorship care intervention * Have previously participated in the Kentucky LEADS Lung Cancer Survivorship Care Program
Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.
U.S. locations
- Markey Cancer CenterLexington, Kentucky
Source and freshness
Processed from ClinicalTrials.gov. Last public update: Feb 23, 2026. Always confirm current availability with the study team.